Generally, the rate of irAE by PD-L1 inhibitors was lower than that of PD-1 inhibitors, including pneumonitis (4.3% vs 2.1%), dermal events (12.4% vs 8.1%), colitis (2.3% vs 1.7%), adrenal insufficiency (0.7% vs 0.2%), nephritis (0.6% vs 0.2%), myositis (0.4% vs 0), rheumatic disease (0.4% vs 0), hypophysitis (0.2% vs 0), and myocarditis (0.1% vs 0, Figure 2B). Here, PDCD1 is linked to pneumonitis.